Harvard Bioscience, Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $22.7 million (+11.1% year over year) and diluted EPS of -$0.64. It usually reports 37–42 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–42 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 11, 2026
42 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
23
+11.1%
|
-3
-27.5%
|
-0.64
-23.1%
|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
21
-4.7%
|
-3
+93.2%
|
-0.77
+93.3%
|
|
Feb 10, 2026
41 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
24
-3.3%
|
-3
-15916.7%
|
-0.06
-15580.8%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
21
-6.3%
|
-1
+74.4%
|
-0.03
+72.7%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
20
-11.5%
|
-2
+22.0%
|
-0.52
-642.9%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
22
-11.2%
|
-50
-972.4%
|
-11.42
-10281.8%
|
|
Mar 12, 2025
71 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
25
-12.8%
|
0
+101.0%
|
0.00
+101.0%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
22
-13.4%
|
-5
-287.6%
|
-0.11
-266.7%
|
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- HBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Holliston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1123494
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Source: SEC EDGAR filings. This is company-reported data, not investment advice.